Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 826 / https://doi.org/10.3332/ecancer.2018.826

Short Communication

Cancer treatment in the last 6 months of life: when inaction can outperform action

When an investigational anticancer drug is being tested, demonstration of improvement in overall survival (OS) will generally lead to regulatory approval. However, the value that improvement in OS adds to patients’ lives is guided largely by the context of the improvement and accompanying trade-offs. For example, when a patient’s life expectancy is less than 6 months, many oncologists will not embark on any active cancer treatments. However, multiple new anticancer drugs have been approved recently after being tested in end-stage cancer patients and demonstrating median OS in the experimental arm close to 6 months. Such practice, particularly when the treatment is also accompanied by serious toxicities and cost, can undermine a peaceful life-death transition. In this commentary, we review regulatory approvals in the last 5 years and the ethical considerations involved in testing active cancer treatment in terminal cancer patients.

Keywords: end of life, financial toxicity, overall survival, serious adverse events, fatal adverse events

Loading Article Metrics ... Please wait

Related articles

Short Communication: Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1

Abstract | Full Article | PDF Published: 30 Apr 2018 / https://doi.org/10.3332/ecancer.2018.831

Conference Report: Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt

Abstract | Full Article | PDF Published: 22 Mar 2018 / https://doi.org/10.3332/ecancer.2018.820

Research: The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima

Abstract | Full Article | PDF | Spanish Published: 18 Jan 2018 / https://doi.org/10.3332/ecancer.2018.799

Review: Natural history of castration-resistant prostate cancer in sub-Saharan African black men: a single-centre study of Nigerian men

Abstract | Full Article | PDF Published: 16 Jan 2018 / https://doi.org/10.3332/ecancer.2018.797

Research: Healthy living and cancer: evidence from UK Biobank

Abstract | Full Article | PDF Published: 04 Jan 2018 / https://doi.org/10.3332/ecancer.2018.792



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence